Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

NCT02845843 is registered in ClinicalTrials.gov with King Abdullah International Medical Research Center as lead sponsor.

NCT NCT02845843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02845843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial
Lead sponsor
King Abdullah International Medical Research Center
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2016
Completion date
May 31, 2020
Enrollment
95 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

middle east respiratory syndrome coronavirus (mers-cov)